新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 葛兰素史克 » GSK和CRT达成癌症表观遗传学研发合作

GSK和CRT达成癌症表观遗传学研发合作

来源:生物谷 2013-11-30 12:40

2013年11月29日讯 /生物谷BIOON/ --葛兰素史克(GSK)、英国癌症研究院(Cancer Research UK)下属商业分部英国癌症研究技术公司(CRT)及英国曼彻斯特大学11月29日达成一项联合研究协议,开发表观遗传学(epigenetics)领域的新抗癌药物。

根据协议,CRT和曼彻斯特大学的科学家,将创造潜在的新药物,靶向于涉及表观遗传学调控的一种关键蛋白。癌症表观遗传学是一门研究癌症分子修饰的学科,这些修饰会改变癌细胞中的基因活性,但不涉及DNA序列的变化。

葛兰素史克(GSK)将为合作项目提供起始原料,并拥有合作所发现的潜在新药分子的独家选择权。CRT将有资格获得相关的里程碑款项,及合作产品在未来销售的特许权使用费。若GSK放弃开发权利,CRT将有权进行进一步的开发。

此次工业界和科学界的合作,将为GSK及CRT带来新的机会,进军新兴癌症生物学中最令人激动的表观遗传学领域,开发新的化合物和不同的方法,来阻止癌症的进展。(生物谷Bioon.com)

英文原文:CRT, University of Manchester and Glaxosmithkline work together to generate new cancer drugs

Friday 29 November 2013
Cancer Research Technology Press Release
Cancer Research Technology, the commercial arm of Cancer Research UK, and the University of Manchester today announced a research agreement with GlaxoSmithKline (GSK) to generate new cancer drugs in the field of epigenetics.

Under the agreement, scientists in the Drug Discovery Unit at the Cancer Research UK Manchester Institute, at the University of Manchester, will create potential new drugs which target a key protein involved in epigenetic regulation.  Cancer epigenetics is the study of molecular modifications which cause changes to the gene activity in cancer cells – but which do not involve a change in the DNA sequence.

Dr Donald Ogilvie, head of the Drug Discovery Unit at Cancer Research UK’s Manchester Institute and part of Manchester Cancer Research Centre, said: “Epigenetic mechanisms are an increasingly important area of cancer research. Directly targeting these mechanisms using our drug discovery platform will provide exciting new opportunities in treating the disease – translating Cancer Research UK’s world-class research into cancer treatments and ultimately providing new options for cancer patients.”

GSK will provide starting materials for the project, and have exclusive option rights to molecules discovered under the collaboration. Cancer Research Technology is eligible to receive development milestone payments as the compounds advance, and royalty payments on net sales of products that result from the collaboration. Cancer Research Technology has the right to develop the molecules further if GSK declines to do so.   

Dr Phil L’Huillier, Cancer Research Technology's director of business development, said: “This important agreement with GSK brings a fresh opportunity to tap into the most exciting areas of emerging cancer biology, and to develop new compounds and different approaches to stop cancer progressing.

“This partnership shows that by combining the experience and skills from industry and academia it is possible to develop projects that may otherwise have taken years to implement – speeding up the development of potential new treatments for cancer.”

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库